Search research articles
Contact Us
Filters
Showing results (1-10 of 194) with videos related to
Page
of 20
Sort By:
Clinical Advances in Hematology & Oncology : H&O
|
November 14, 2006
Anticoagulation regimens for thalidomide and lenalidomide
Maurizio Zangari
Bone
|
March 8, 2016
The effects of proteasome inhibitors on bone remodeling in multiple myeloma
Maurizio Zangari, Larry J Suva
Current Opinion in Supportive and Palliative Care
|
July 27, 2010
Bone and paraproteinemias
Maurizio Zangari, Fenghuang Zhan, Guido Tricot
European Journal of Haematology
|
May 25, 2012
Low-risk identification in multiple myeloma using a new 14-gene model
Tiehua Chen, Tamara Berno, Maurizio Zangari
Current Pharmaceutical Biotechnology
|
December 16, 2006
Farnesyltransferase inhibitors and rapamycin in the treatment of multiple myeloma
Maurizio Zangari, Federica Cavallo, Guido Tricot
Biomed Research International
|
May 23, 2015
Drug resistance in hematologic malignancies: induction mechanisms, genetics, and therapeutics
Fenghuang Zhan, Maurizio Zangari, Lugui Qiu
Expert Opinion on Investigational Drugs
|
November 1, 2005
Immunomodulatory drugs in multiple myeloma
Maurizio Zangari, Francesca Elice, Guido Tricot
Cancer Treatment and Research
|
April 21, 2009
Bleeding disorders associated with cancer dysproteinemias
Maurizio Zangari, F Elice, G Tricot, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 18, 2011
Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens
Maurizio Zangari, Louis Fink, Fenghuang Zhan, et al.
Seminars in Oncology
|
January 10, 2003
High-dose therapy and immunomodulatory drugs in multiple myeloma
Bart Barlogie, John Shaughnessy, Maurizio Zangari, et al.
Page
of 20
Search research articles
Search
Showing results (1-10 of 194) with videos related to
Sort By:
Page
of 20
Clinical Advances in Hematology & Oncology : H&O
|
November 14, 2006
Anticoagulation regimens for thalidomide and lenalidomide
Maurizio Zangari
Bone
|
March 8, 2016
The effects of proteasome inhibitors on bone remodeling in multiple myeloma
Maurizio Zangari, Larry J Suva
Current Opinion in Supportive and Palliative Care
|
July 27, 2010
Bone and paraproteinemias
Maurizio Zangari, Fenghuang Zhan, Guido Tricot
European Journal of Haematology
|
May 25, 2012
Low-risk identification in multiple myeloma using a new 14-gene model
Tiehua Chen, Tamara Berno, Maurizio Zangari
Current Pharmaceutical Biotechnology
|
December 16, 2006
Farnesyltransferase inhibitors and rapamycin in the treatment of multiple myeloma
Maurizio Zangari, Federica Cavallo, Guido Tricot
Biomed Research International
|
May 23, 2015
Drug resistance in hematologic malignancies: induction mechanisms, genetics, and therapeutics
Fenghuang Zhan, Maurizio Zangari, Lugui Qiu
Expert Opinion on Investigational Drugs
|
November 1, 2005
Immunomodulatory drugs in multiple myeloma
Maurizio Zangari, Francesca Elice, Guido Tricot
Cancer Treatment and Research
|
April 21, 2009
Bleeding disorders associated with cancer dysproteinemias
Maurizio Zangari, F Elice, G Tricot, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 18, 2011
Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens
Maurizio Zangari, Louis Fink, Fenghuang Zhan, et al.
Seminars in Oncology
|
January 10, 2003
High-dose therapy and immunomodulatory drugs in multiple myeloma
Bart Barlogie, John Shaughnessy, Maurizio Zangari, et al.
Page
of 20